Head-to-head · Cost-Efficiency Index
Trimrose vs Evernow
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Trimrose
Shoppers who want a named medical director and pharmacy partners plus the option to step up to branded GLP-1s on the same platform.
Visit TrimroseEvernow
Cost-first shoppers who want women 40+ wanting GLP-1 prescribing integrated with menopause/hormone care, ideally with insurance.
Visit EvernowThe verdict
Trimrose takes it, leading the Cost-Efficiency Index 50 to 49. TrimRose (trimrose.health) is a LegitScript-verified telehealth platform offering compounded semaglutide (from $269/mo) and tirzepatide (from $359/mo), plus branded Ozempic and Wegovy at much higher prices. Evernow still earns a C — Cost-first shoppers who want women 40+ wanting GLP-1 prescribing integrated with menopause/hormone care, ideally with insurance.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Trimrose.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Trimrose | Evernow |
|---|---|---|
| Cost-Efficiency Index | 50/100 | 49/100 |
| Semaglutide / mo | $269/mo (starting dose, compounded) | Not disclosed |
| Tirzepatide / mo | $359/mo (starting dose, compounded) | Not disclosed |
| Semaglutide / yr (modeled) | $3,228 | — |
| Tirzepatide / yr (modeled) | $4,308 | — |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | Yes | No |
| Brand-name access | Yes | Yes |
| Rank here | #415 | #421 |
Trimrose
50/100Where the value is
- LegitScript-verified with a displayed seal
- Named medical directors with public NPI numbers, unusual transparency versus peers
- Four named, identifiable compounding pharmacy partners
The tradeoffs
- All prices are 'starting at' floors -- actual monthly cost rises with dose and is not fully disclosed upfront
- A separate $60 first-visit fee is layered on top of the monthly medication price
Evernow
49/100Where the value is
- Confirmed genuine GLP-1 prescribing (not hormone-therapy-only, despite the brand's menopause focus)
- Only prescribes FDA-approved branded medications, no compounded-drug quality uncertainty
- Available in all 50 states plus D.C.
The tradeoffs
- No cash-pay price published anywhere -- cost is insurance-dependent and opaque to uninsured shoppers
- No compounded option for patients priced out of branded GLP-1s
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.